Related Experiment Video

Updated: Apr 19, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Genetic susceptibility to idiopathic membranous nephropathy in high-prevalence Area, Taiwan

Shih-Yin Chen1, Cheng-Hsu Chen2, Yu-Chuen Huang3

  • 1Genetics Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan ; Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan ; Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan.

Biomedicine
|December 19, 2014
PubMed

Insights

Idiopathic membranous nephropathy (MN) is a kidney disease causing nephrotic syndrome. New research identifies KIRREL2 gene variations as potential causes, aiding diagnosis and prognosis.

Area of Science:

  • Nephrology
  • Genetics
  • Immunology

Background:

  • Idiopathic membranous nephropathy (MN) is a primary cause of nephrotic syndrome in adults.
  • Approximately 75% of adult MN cases are idiopathic, with 25% progressing to end-stage renal disease.
  • Pathogenesis involves immune complex deposition, but the exact mechanisms remain unclear.

Purpose of the Study:

  • To review the epidemiology of idiopathic membranous nephropathy.
  • To investigate the association of KIRREL2 gene polymorphisms (rs443186 and rs447707) with MN.
  • To explore potential genetic factors for MN diagnosis and prognosis.

Main Methods:

  • Literature review on MN epidemiology.
  • Genetic analysis of KIRREL2 polymorphisms (rs443186 and rs447707) in MN patients.
  • Comparison of findings with previously identified associated genes (IL-6, NPHS1, TLR-4, TLR-9, STAT4, MYH9).

Main Results:

  • Identified KIRREL2 (rs443186 and rs447707) polymorphisms as potential underlying causes of MN.
  • Highlighted the role of genetic factors in MN pathogenesis.
  • Reinforced the association of other genes (IL-6, NPHS1, TLR-4, TLR-9, STAT4, MYH9) with primary MN.

Conclusions:

  • KIRREL2 gene variations warrant further investigation as potential causes of idiopathic membranous nephropathy.
  • Genetic polymorphisms may offer valuable tools for MN diagnosis and prognosis.
  • Continued research into genetic associations is crucial for understanding MN.
Keywords:
HaplotypeMembranous glomerulonephritis (MN)Single nucleotide polymorphisms (SNPs)

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.9K
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.2K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
83
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.4K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
198
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74